The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCV
Open accessAbstract
Data show that viral genotype 1 may increase the risk of cirrhosis and hepatocellular carcinoma (HCC) compared to genotype 2 in patients with chronic hepatitis C virus (HCV) infection. However, the effect of HCV genotype 3 on cirrhosis and HCC risk is uncertain. We identified patients with active HCV infection, confirmed by positive polymerase chain reaction (PCR) and a known HCV genotype, from the VA HCV Clinical Case Registry between 2000 and 2009. We examined the effect of HCV genotype on the risk of cirrhosis and HCC in a Cox proportional hazards model adjusting for patients' age, period of service (World War I/II, Vietnam era, post-Vietnam era), race, gender, human immunodeficiency virus (HIV) infection, alcohol use, diabetes, body mass index, and antiviral treatment receipt. Of the 110,484 patients with active HCV viremia, 88,348 (79.9%) had genotype 1, 13,077 (11.8%) genotype 2, 8,337 (7.5%) genotype 3, and 1,082 (0.9%) patients had genotype 4 infection. Despite being younger, patients with genotype 3 had a higher risk of developing cirrhosis (unadjusted hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.32-1.50) and HCC (unadjusted HR = 1.66, 95% CI = 1.48-1.85) than HCV genotype 1 patients. After adjustment for prespecified demographic, clinical, and antiviral treatment factors, the risk of cirrhosis and HCC was 31% (adjusted HR = 1.31, 95% CI = 1.22-1.39) and 80% (adjusted HR = 1.80, 95% CI = 1.61-2.03) higher in patients with genotype 3 compared to genotype 1 infected patients. Conclusion : HCV genotype 3 is associated with a significantly increased risk of developing cirrhosis and HCC compared to HCV genotype 1. This association is independent of patients' age, diabetes, body mass index, or antiviral treatment. (Hepatology 2014;60:98–105)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S. C., Schultz, M., Davis, M. N., Kayali, Z., Reddy, K. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214853 · Cited by 1,788
van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., et al. (2012) · JAMA · doi:10.1001/jama.2012.144878 · Cited by 1,510
Natural history of chronic hepatitis C
Seeff, L. B. (2002) · Hepatology · doi:10.1053/jhep.2002.36806 · Cited by 1,424
[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Jacobson, I. M., Gordon, S. C., Kowdley, K. V., Yoshida, E. M., Rodriguez-Torres, M., Sulkowski, M. S., Shiffman, M. L., Lawitz, E., Everson, G., Bennett, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214854 · Cited by 1,090
Davis, G. L., Alter, M. J., El–Serag, H., Poynard, T., & Jennings, L. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.067 · Cited by 878
Self-citationSteatosis affects chronic hepatitis C progression in a genotype specific way
Rubbia-Brandt, L., Fabris, P., Paganin, S., Leandro, G., Male, P.-J., Giostra, E., Carlotto, A., Bozzola, L., Smedile, A., & Negro, F. (2004) · Gut · doi:10.1136/gut.2003.018770 · Cited by 297
Westin, J., Nordlinder, H., Lagging, M., Norkrans, G., & Wejstål, R. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00299-4 · Cited by 280
KRAMER, J. R., DAVILA, J. A., MILLER, E. D., RICHARDSON, P., GIORDANO, T. P., & EL‐SERAG, H. B. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03572.x · Cited by 268
Self-citationDisease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors
Missiha, S. B., Ostrowski, M., & Heathcote, E. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.069 · Cited by 228
Predictors of response of U.S. veterans to treatment for the hepatitis C virus
Backus, L. I., Boothroyd, D. B., Phillips, B. R., & Mole, L. A. (2007) · Hepatology · doi:10.1002/hep.21662 · Cited by 225
Raimondi, S., Bruno, S., Mondelli, M. U., & Maisonneuve, P. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.01.019 · Cited by 224
Nkontchou, G., Ziol, M., Aout, M., Lhabadie, M., Baazia, Y., Mahmoudi, A., Roulot, D., Ganne-Carrie, N., Grando-Lemaire, V., Trinchet, J.-C., et al. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01441.x · Cited by 179
Probst, A., Dang, T., Bochud, M., Egger, M., Negro, F., & Bochud, P.-Y. (2011) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2011.01481.x · Cited by 161
Backus, L. I., Gavrilov, S., Loomis, T. P., Halloran, J. P., Phillips, B. R., Belperio, P. S., & Mole, L. A. (2009) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m3203 · Cited by 104
Piodi, A., Chouteau, P., Lerat, H., et al. (2008) · Hepatology · doi:10.1002/hep.22288 · Cited by 82
Adverse Outcomes in Alaska Natives Who Recovered From or Have Chronic Hepatitis C Infection
McMahon, B. J., Bruden, D. J. T., Bruce, M. G., Livingston, S., Christensen, C., Homan, C., Hennessy, T. W., Williams, J. L., Sullivan, D., Rosen, H. R., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.056 · Cited by 45
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Epidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Self-citationTranslating RNA sequencing into clinical diagnostics: opportunities and challenges
Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.10 · Cited by 809
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316145 · Cited by 795
Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Massarweh, N. N., & El-Serag, H. B. (2017) · Cancer Control · doi:10.1177/1073274817729245 · Cited by 634
Self-citation
Metadata
- Authors
- Kanwal, F., Kramer, J. R., Ilyas, J., Duan, Z., & El-Serag, H. B.
- Venue
- Hepatology
- Published
- 2014-07
- Volume
- 60
- Issue
- 1
- Pages
- 98-105
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2083200314
- Cited by
- 322
- References
- 18
- FWCI
- 17.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.